Asignificant proportion of deaths from alcoholic. Theophylline Improves Steroid Sensitivity in Acute Alcoholic Hepatitis
|
|
- Calvin Bell
- 5 years ago
- Views:
Transcription
1 Theophylline Improves Steroid Sensitivity in Acute Alcoholic Hepatitis Stuart F. W. Kendrick, Elsbeth Henderson, Jeremy Palmer, David E. J. Jones, and Chris P. Day Corticosteroid therapy has shown some benefit in severe acute alcoholic hepatitis (AAH); however, this is limited by uncertainty in patient selection and variable clinical response. Theophylline has been shown to ameliorate impaired steroid sensitivity in chronic obstructive pulmonary disease by facilitating corticosteroid-induced silencing of proinflammatory genes. We aimed to explore the mechanistic basis of the variable response to corticosteroid therapy seen in patients with AAH and to address the extent to which theophylline can improve this response. The ability of dexamethasone to inhibit phytohemagglutinin-induced lymphocyte proliferation was assessed by 3 H-thymidine incorporation in 12 severe AAH patients and age-matched and sex-matched controls. Steroid sensitivity was measured in terms of I max, the maximum inhibition of proliferation. The effect of M theophylline and, in survivors, change in I max during recovery were observed. Lymphocyte steroid sensitivity was found to be significantly reduced in AAH compared with controls (I max 67[64.5]% versus 95[62.3]%, P ) and correlated with clinical markers of steroid responsiveness. In survivors, I max increased in recovery. Theophylline M significantly increased lymphocyte steroid sensitivity (I max 86[66.6]% versus 67[65.0]%, P ). Conclusion: Acute alcoholic hepatitis is associated with significant lymphocyte steroid insensitivity, which improves in recovery and can be ameliorated ex vivo by theophylline. This offers potential to rationalize corticosteroid prescribing in AAH and, furthermore, justifies investigation of this novel role for an existing pharmacological agent in this common and frequently fatal condition. (HEPATOLOGY 2010;52: ) Asignificant proportion of deaths from alcoholic liver disease occur in patients with rapidly progressive liver failure caused by acute alcoholic hepatitis (AAH). Patients who die of AAH frequently do so on their first presentation to health services, and Abbreviations: AAH, acute alcoholic hepatitis; COPD, chronic obstructive pulmonary disease; ECBL, early change in bilirubin level; HDAC histone deacetylase; I max, maximum inhibition; IC 50, concentration for half maximal inhibition; IL, interleukin. From the Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK. Received October 26, 2009; accepted March 8, Supported by a Medical Research Council (UK) Clinical Research Training Fellowship to S.F.W.K. (G ). The funder had no role in study design or the collection, analysis, and interpretation of data.. Address reprint requests to: Stuart F. W. Kendrick, Institute of Cellular Medicine, Newcastle University Medical School, Framlington Place, Newcastle upon Tyne, NE2 4HH United Kingdom. stuart.kendrick@ncl.ac.uk; fax: (44) Copyright VC 2010 by the American Association for the Study of Liver Diseases. Published online in Wiley InterScience ( DOI /hep Potential conflict of interest: Nothing to report. Additional Supporting Information may be found in the online version of this article. so do not have the opportunity to reap the benefits of health education and abstinence. A dearth of applicable and effective therapeutic options means that mortality remains at approximately 30% in the most severely affected patients. 1 It is well established that AAH is characterized by a significant inflammatory response with histological inflammatory cell infiltrate and high circulating levels of pro-inflammatory cytokines, including interleukin (IL)-6, IL-8, and tumor necrosis factor alpha, being seen in AAH patients. 2-5 The presence of such an inflammatory element to AAH provides an obvious potential approach to therapy through anti-inflammatory drugs such as corticosteroids. Indeed, in metaanalysis corticosteroid therapy has been demonstrated to have a moderate effect on outcome in the group at highest risk of death, reducing 1-month mortality from 35% to 16%. 1 However, one in six patients in this group die despite treatment, and the applicability of corticosteroid therapy is limited by concerns about heightened risks of sepsis and gastrointestinal hemorrhage. Steroid responsiveness in AAH is indicated by an early change in the serum bilirubin level (ECBL), 126
2 HEPATOLOGY, Vol. 52, No. 1, 2010 KENDRICK ET AL. 127 with those patients whose bilirubin has not fallen by the seventh day of treatment having a particularly high mortality and gaining no benefit from continuation of therapy. 6 Treatment outcomes could be improved by early identification of the 27% of patients who are unlikely to benefit from steroids or by strategies to improve steroid sensitivity in this group. Impaired steroid responsiveness is not, however, unique to AAH. It has been well characterized in inflammatory skin diseases and ulcerative colitis, where it is evident as a reduced maximum inhibitory effect of dexamethasone on ex vivo phytohemagglutininstimulated lymphocyte proliferation. 7 Its prevalence is higher in chronic obstructive pulmonary disease (COPD), in which it has been shown to result from smoking-induced abnormalities in transcriptional regulation of pro-inflammatory genes (through reduced capacity of the glucocorticoid receptor to recruit histone deacetylases (HDACs) to actively transcribed proinflammatory genes because of the inhibitory effect of smoking-induced oxidative stress 8 ). The traditional bronchodilator theophylline was shown to counteract this effect, exerting an anti-inflammatory effect by improving HDAC recruitment to silence pro-inflammatory genes, 9 even at 10 5 M, a concentration at which clinically useful bronchodilator effects do not occur. In this study, we set out to explore corticosteroid insensitivity in AAH using an ex vivo approach and to explore the hypothesis that in vitro corticosteroid sensitivity can be improved by the actions of theophylline, thereby identifying theophylline as a potential novel therapeutic agent for the treatment of AAH. Patients and Methods Patients with a primary diagnosis of acute alcoholic hepatitis admitted to Newcastle upon Tyne Hospitals NHS Foundation Trust between October 2006 and March 2008 were invited to participate in the study if they fulfilled the accepted criteria for corticosteroid therapy (Maddrey discriminant function > 32, equating to a 35% 28-day mortality without treatment 10 ). Patients were excluded if they had gastrointestinal bleeding, sepsis, recent surgery, or inflammatory disease, or were already receiving immunomodulatory therapy. Alternative causes of liver dysfunction were excluded by duplex ultrasonography and blood testing for hepatitis A, B, C, and E, ferritin, and HFE genotype, ceruloplasmin, alpha-1-antitrypsin, immunoglobulins, thyroid-stimulating hormone, antinuclear antibody, anti-smooth muscle antibody, antimitochondrial antibody, anti-liver/kidney microsomal antibody, antisoluble liver antigen antibody, and anti-neutrophil cytoplasmic antibody. Liver biopsy was performed only when there was thought to be a significant probability of it altering clinical management or outcome. In patients who did not undergo biopsy, the presence of coexisting cirrhosis was determined either from diagnostic imaging or from the presence of varices at endoscopy. Age-matched and sex-matched controls were recruited locally. Control exclusion criteria were alcohol intake greater than 40 units per week for men and 30 units per week for women, active infection or inflammatory disease, surgery, trauma or immunomodulatory therapy. Patient and control characteristics are summarized in Table 1. None of the study subjects were receiving corticosteroid therapy at the time of their participation in the study. Patients were subsequently treated with oral prednisolone 40 mg daily for 28 days. Treatment was discontinued early in eight patients, four because of evidence of poor clinical response and four because of concern about sepsis or bleeding. Lymphocyte steroid sensitivity was assessed at recruitment and, for surviving patients who attended follow-up, at 4-weekly intervals for 6 months. The study protocol was prospectively approved by the Local Research Ethics Committee, and informed consent was obtained for each participant. Peripheral blood mononuclear cells were isolated from 25 ml blood by density centrifugation (Lymphoprep, Axis-Shield, Norway, Leucosep tubes, Greiner Bio-One, Germany) and washed three times in phosphate-buffered saline cells were added to each of 24 wells of a 96-well tissue culture plate in a final volume of 200 ll Roswell Park Memorial Institute medium with 2 mm L-glutamine and 10% fetal bovine serum (Lonza, UK). Seven triplicates were stimulated with the mitogen phytohemagglutinin (Sigma, St. Louis, MO) at a final concentration of 5 lg/ml. Six of these triplicates were treated with dexamethasone (Sigma) in serial 1:10 dilutions to give final concentrations from 10 6 to M. For the initial patient samples, the reaction was duplicated in the presence of 10 5 M theophylline (Sigma). Plates were incubated at 37 Cin5%CO 2 for 72 hours. Proliferation was measured by incorporation of tritiated thymidine (Amersham Biosciences, UK). To each well was added 5.29 nmol (37 kbq of activity), and it was incubated for a further 16 hours. Well contents were aspirated onto filter mats (Wallac, Finland) by a cell harvester (Harvester 96 Mach II, Tomtec, Hamden, CT), and radioactivity of the aspirate was determined by
3 128 KENDRICK ET AL. HEPATOLOGY, July 2010 beta-counter (MicroBeta TriLux; PerkinElmer, Waltham, MA). Incorporated 3 H-thymidine activity counts were corrected for background and normalized to uninhibited proliferation without dexamethasone. Proliferative response was plotted against dexamethasone concentration, a curve was fitted, and the maximum inhibition of proliferation (I max ) and the concentration of dexamethasone required to achieve 50% of maximal inhibition (IC 50 ) were calculated (Prism 4; Graph Pad, La Jolla CA). 7 Mean (6standard error) I max was compared between groups using the Mann-Witney U test (unpaired observations) and Wilcoxon signed-rank test (paired observations). Results Table 1. Patient and Control Characteristics Characteristic AAH Patients (n 5 12) Normal Controls (n 5 12) Male Age (years) 47 (34-60) 51 (34-65) Weekly ethanol (units) 117 (20-560) 19 (7-40) Maddrey DF 61 (32-141) Biopsied 2 0 Biopsy evidence of cirrhosis 2 Circumstantial evidence of cirrhosis only 4 Values are mean (range). DF, discriminant function. Representative control and patient lymphocyte steroid sensitivity curves are shown in Fig. 1. Mean ex vivo steroid sensitivity as determined by I max was significantly lower in AAH patients than in controls (67% 6 4.5% versus 95% 6 2.3%, P < , Fig. 2), suggesting a significantly higher level of corticosteroid insensitivity in patients with AAH than in normal controls. Evidence of established cirrhosis (n ¼ 6) was not associated with significant difference in I max (63% 6 4.9% versus 72% 6 7.4%, P ¼ 0.31, Supporting Fig. 1). Groups did not differ significantly in mean IC 50 ( versus nmol/l, P ¼ 0.98, data not shown). Within the AAH group, mean I max was greater in those patients who showed an early change in bilirubin level, an established clinical marker of glucocorticoid responsiveness in AAH, than in those whose bilirubin had not fallen by 7 days (74% 6 5.8% versus 58% 6 4.7%, P < 0.05, Fig. 3), suggesting that corticosteroid insensitivity in the in vitro assay is a predictor of subsequent clinical response to corticosteroid therapy. However, this study did not detect a difference in I max between those who died during treatment and those who survived (65.7% 6 8.2% versus 68.1% 6 5.6%, P ¼ 0.93, data not shown). Within the AAH group, eight patients survived and seven attended for at least one follow-up appointment. Of these, six reported abstinence from alcohol since admission. Mean I max in this group was significantly higher during recovery than at presentation (92% 6 4.9% versus 70% 6 7.4%, P ¼ 0.01, Fig. 4). The addition of Theophylline 10 5 M (a concentration previously demonstrated to modulate inflammation in COPD 9 ) to the lymphocyte steroid sensitivity reaction resulted in an increase in I max measured at presentation (86% 6 6.6% versus 67% 6 5.0%, P < 0.05, Fig. 5). In this study, no relationships were seen between I max and smoking status (P ¼ 0.32), reported weekly alcohol intake (r 2 ¼ 0.007), or disease severity as measured by serum bilirubin, prothrombin time, Fig. 1. Representative patient and control lymphocyte steroid sensitivity curves in peripheral blood mononuclear cells from control subjects (A) and patients with acute alcoholic hepatitis. (B) T lymphocyte proliferation was stimulated with phytohemagglutinin and suppressed with increasing concentrations of dexamethasone. At each concentration, proliferation was measured by incorporation of a radiolabeled nucleotide into new cells and expressed as a percentage of uninhibited proliferation in the absence of dexamethasone. For each subject, the maximum inhibition of proliferation (I max ) and the dexamethasone concentration required to achieve 50% of maximal inhibition (IC 50 ) were calculated. Values are mean 6 SEM.
4 HEPATOLOGY, Vol. 52, No. 1, 2010 KENDRICK ET AL. 129 Fig. 2. Lymphocyte steroid sensitivity in acute alcoholic hepatitis patients and normal controls. Steroid sensitivity is measured in terms of I max, the maximal percentage inhibition of proliferation by dexamethasone. Bars represent mean I max in each group. AAH, acute alcoholic hepatitis. creatinine, albumin, or discriminant function, Child- Pugh, 11 MELD, 12 or Glasgow Alcoholic Hepatitis 13 scores (r 2 < 0.15 for each). Discussion Fig. 4. Change in lymphocyte steroid sensitivity after recovery from acute alcoholic hepatitis. Representative steroid sensitivity curves for the same patient at presentation and after recovery are illustrated in (A). Steroid sensitivity in terms of I max is plotted at presentation and after recovery for surviving patients attending follow-up in (B). Fig. 3. Clinical correlation of ex vivo steroid sensitivity. Relationship between ex vivo lymphocyte steroid sensitivity expressed as I max and early change in bilirubin level (ECBL), a clinical marker of steroid responsiveness in acute alcoholic hepatitis defined as any fall in bilirubin at day 7. Boxes represent the interquartile range divided at the median, with whiskers covering the whole range of the data. The sensitivity of mitogen-stimulated lymphocyte proliferation to glucocorticoids is a well-established correlate of clinical steroid responsiveness in asthma, rheumatoid arthritis, renal transplantation, and ulcerative colitis. 7,14-16 Lymphocyte proliferative responses to liver-derived antigens are a feature of human alcoholic liver disease, 17 and steroid therapy is effective in a proportion of patients with AAH. 1. This study investigated ex vivo lymphocyte steroid sensitivity in patients with clinically severe AAH and found it to be significantly lower than in age-matched and sex-matched controls. As is the case in steroid-resistant ulcerative colitis, the reduced steroid sensitivity in AAH was apparent in differences in the maximum inhibition of proliferation I max, a measure of steroid efficacy, rather than in the IC 50, which measures steroid potency. 7 This implies that steroid resistance is unlikely to be overcome simply by increasing the steroid dose. The clinical marker of any fall in bilirubin by day 7 on treatment (ECBL) has been shown to identify patients who are clinically steroid responsive, with a 95% 6-month survival after treatment, as opposed to those with no fall in bilirubin
5 130 KENDRICK ET AL. HEPATOLOGY, July 2010 Fig. 5. Change in ex vivo lymphocyte steroid sensitivity with addition of theophylline. In acute alcoholic hepatitis patients, lymphocyte steroid sensitivity was determined at presentation in the presence and absence of theophylline 10 5 M. Representative steroid sensitivity curves for a patient s lymphocytes with and without theophylline are illustrated in (A). Steroid sensitivity in terms of I max is plotted in the absence and presence of 10 M theophylline in (B). whose 6-month survival is 25% and who do not benefit from continuation of glucocorticoid therapy. 6 In our study, mean steroid sensitivity as measured by I max was significantly lower in those patients who showed no ECBL, suggesting that, as in other diseases, I max is an ex vivo correlate of clinical steroid responsiveness in AAH. The relatively small number of patients in this study limited its power to detect a relationship between survival and I max in corticosteroid-treated patients, and it would be valuable to confirm the relationship between in vitro findings and clinical response in a larger sample. Further refinement of this technique might allow ineffective steroid therapy to be stopped at day 4 or earlier, helping to minimize steroid-related morbidity. The high prevalence of reduced I max in patients relative to controls strongly suggests that steroid resistance is a feature of AAH. However, there is known to be wide interindividual variation in steroid sensitivity, with studies suggesting that up to 30% of the healthy population would fail to respond to steroid therapy for severe inflammatory conditions. 18 This raises the question of whether the patients with AAH are those who are intrinsically steroid resistant (suggesting that this intrinsic steroid insensitivity might predispose to severe AAH in heavy drinkers) or whether steroid resistance occurs as a consequence of earlier events in the pathogenesis of AAH. Our observation that in survivors of AAH I max tends to increase (though not always normalize) during recovery suggests that steroid resistance is at least in part a consequence rather than a cause of the development of AAH. There was no relationship between weekly alcohol intake and I max in our sample, but further study could investigate whether steroid insensitivity in other inflammatory conditions correlates with alcohol intake, and whether heavy drinkers without liver disease demonstrate relative steroid insensitivity by the same assay. Glucocorticoid modulation of inflammatory responses results from the ability to control transcription of proinflammatory genes via a number of mechanisms, including the recruitment of HDACs to silence actively transcribed pro-inflammatory genes. Failure of HDAC recruitment leads to steroid insensitivity and ongoing inflammation. 8 The oxidative stress associated with cigarette smoking has been shown to have this effect in COPD. No association between I max and smoking history was observed in our patient sample. However, ethanol metabolism is itself a potent source of reactive oxygen species, which may impair the ability of the glucocorticoid receptor to recruit HDACs to switch off transcription of proinflammatory genes by the same mechanism. Alternatively, we have recently demonstrated that the increased concentrations of free acetate generated by ethanol metabolism favor increased histone acetylation and enhanced proinflammatory gene expression in a cell-line model of AAH, 19 and this mechanism could antagonize the normal glucocorticoid effect. In our ex vivo assay, the addition of theophylline improved (but not always normalized) steroid sensitivity as measured by I max. Theophylline has a similar effect on steroid sensitivity in COPD, where it has been shown to improve HDAC recruitment at the same concentration (10 5 M), 9 which is below the plasma concentration associated with a clinically significant bronchodilator action. The same mechanism could be responsible for the increased I max observed in the AAH patient samples. Alternatively, theophylline
6 HEPATOLOGY, Vol. 52, No. 1, 2010 KENDRICK ET AL. 131 may be exerting its effect through phosphodiesterase inhibition; a role has recently been demonstrated for PDE4B in the enhanced inflammatory responses observed after chronic ethanol exposure. 20 However, significant phosphodiesterase effects are unlikely at the relatively low concentration of theophylline used in this study. 9 Of interest is the fact that theophylline is a hepatic metabolite of caffeine and coffee drinking has been shown to protect against advanced alcoholic liver disease in large epidemiological studies. 21 Furthermore, pentoxifylline, another methyl xanthine compound similar in structure to both caffeine and theophylline with documented antitumor necrosis factor alpha properties, has been shown in trials to improve survival in AAH. 22 Pentoxifylline has been found to be ineffective as salvage therapy in AAH patients who have failed to respond to corticosteroids, 23 but true combination therapy has not been tested. The mechanism of action of both pentoxifylline and theophylline in this setting remains to be fully investigated, and it is possible that theophylline provides a different or a more potent pharmacological effect. This study highlights the possibility for existing, inexpensive treatments to be used more effectively in a common and frequently fatal condition. Early and more accurate determination of steroid sensitivity has the potential to rationalize corticosteroid treatment to minimize unwanted effects and maximize clinical benefit. The potential of low-dose theophylline to increase steroid sensitivity leads us to suggest that a clinical trial of its use in acute alcoholic hepatitis could inform and improve future clinical practice. Acknowledgment: The authors thank the study participants for their time and commitment and acknowledge the support of their medical and nursing staff. References 1. Mathurin P, Mendenhall CL, Carithers RL, Ramond M-J, Maddrey WC, Garstide P, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J Hepatol 2002;36: Baptista A. Alcoholic liver disease: morphological manifestations. Review by an international group. Lancet 1981;1: Bird G, Sheron N, Goka A, Alexander G, Williams R. Increased plasma tumor necrosis factor in severe alcoholic hepatitis. Ann Intern Med 1990;112: Sheron N, Bird G, Goka J, Alexander G, Williams R. Elevated plasma interleukin-6 and increased severity and mortality in alcoholic hepatitis. Clin Exp Immunol 1991;84: Sheron N, Bird G, Koskinas J, Portmann B, Ceska M, Lindley I, et al. Circulating and tissue levels of the neutrophil chemotaxin interleukin-8 are elevated in severe acute alcoholic hepatitis, and tissue levels correlate with neutrophil infiltration. HEPATOLOGY 1993;18: Mathurin P, Abdelnour M, Ramond M-J, Carbonell N, Fartoux L, Serfaty L, et al. Early change in bilirubin levels is an important prognostic factor in severe alcoholic hepatitis treated with prednisolone. HEPATO- LOGY 2003;38: Hearing SD, Norman M, Probert CSJ, Haslam N, Dayan CM. Predicting therapeutic outcome in severe ulcerative colitis by measuring in vitro steroid sensitivity of proliferating peripheral blood lymphocytes. Gut 1999;45: Barnes PJ, Ito K, Adcock IM. Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase. Lancet 2004;363: Barnes PJ. Theophylline in chronic obstructive pulmonary disease: new horizons. Proc Am Thorac Soc 2005;2: Carithers RJ, Herlong H, Diehl A, Shaw E, Combes B, Fallon H, et al. Methylprednisolone therapy in patients with severe alcoholic hepatitis: a randomized multicenter trial. Ann Intern Med 1989;110: Christensen E, Schlichting P, Fauerholdt L, Gluud C, Andersen PK, Juhl E, et al. Prognostic value of Child-Turcotte criteria in medically treated cirrhosis. HEPATOLOGY 1984;4: Dunn W, Jamil LH, Brown LS, Wiesner RH, Kim WR, Menon KVN, et al. MELD accurately predicts mortality in patients with alcoholic hepatitis. HEPATOLOGY 2005;41: Forrest EH, Evans CDJ, Stewart S, Phillips M, Oo YH, McAvoy NC, et al. Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut 2005;54: Corrigan CJ, Brown PH, Barnes NC, Szefler SJ, Tsai JJ, Frew AJ, et al. Glucocorticoid resistance in chronic asthma: glucocorticoid pharmacokinetics, glucocorticoid receptor characteristics, and inhibition of peripheral blood T cell proliferation by glucocorticoids in vitro. Am Rev Respir Dis 1991;144: Kirkham BW, Corkill MM, Davison SC, Panayi GS. Response to glucocorticoid treatment in rheumatoid arthritis: in vitro cell mediated immune assay predicts in vivo responses. J Rheumatol 1991;18: Langhoff E, Ladefoged J, Jakobsen BK, Platz P, Ryder LP, Svejgaard A, et al. Recipient lymphocyte sensitivity to methylprednisolone affects cadaver kidney graft survival. Lancet 1986;1: Stewart SF, Vidali M, Day CP, Albano E, Jones DEJ. Oxidative stress as a trigger for cellular immune responses in patients with alcoholic liver disease. HEPATOLOGY 2004;39: Hearing SD, Norman M, Smyth C, Foy C, Dayan CM. Wide variation in lymphocyte steroid sensitivity among healthy human volunteers. J Clin Endocrinol Metab 1999;84: Kendrick SFW, O Boyle G, Mann J, Zeybel M, Palmer J, Jones D, et al. Acetate, the key modulator of inflammatory responses in acute alcoholic hepatitis. HEPATOLOGY 2010; doi: /hep Gobejishvili L, Barve S, Joshi-Barve S, McClain C. Enhanced PDE4B expression augments LPS-inducible TNF expression in ethanol-primed monocytes: relevance to alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol 2008;295:G718-G Klatsky AL, Morton C, Udaltsova N, Friedman GD. Coffee, cirrhosis, and transaminase enzymes. Arch Intern Med 2006;166: Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 2000;119: Louvet A, Diaz E, Dharancy S, Coevoet H, Texier F, Thevenot T, et al. Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids. J Hepatol 2008;48:
Indian Journal of Basic and Applied Medical Research; June 2017: Vol.-6, Issue- 3, P
Original article: Study of usefulness of Discriminant Function (DF) and Glasgow Alcoholic Hepatitis Score (GAHS) in treatment of patients of Alcoholic Hepatitis in Indian Population Dr Mugdha Thakur, Dr
More informationOVERVIEW OF ALD ALCOHOLIC LIVER DISEASE DISCLOSURE
ALCOHOLIC LIVER DISEASE KEVIN D MULLEN MD West Virginia University Morgantown WV DISCLOSURE I have nothing to disclose. AMOUNT OF ALCOHOL PER STANDARD DRINK > (30 ) GRAM OF ALCOHOL PER DAY USA Canada UK
More informationAlcoholic Hepatitis. Christian Doppler Research Laboratory for Gut Inflammation Medical University Innsbruck. Herbert Tilg
Alcoholic Hepatitis Christian Doppler Research Laboratory for Gut Inflammation Medical University Innsbruck Herbert Tilg Overview Background I: Alcoholic steatohepatitis (ASH) is a severe and often life-threatening
More informationTreatment of Alcoholic Hepatitis
REVIEW REVIEW Treatment of Alcoholic Hepatitis Timothy R. Morgan, M.D.,*, Daniel Chao, M.D,*, Gregory Botwin, M.D. Three steps must be completed before starting treatment for alcoholic hepatitis (AH).
More informationAlcoholic hepatitis (AH) is an acute, inflammatory. MELD Accurately Predicts Mortality in Patients With Alcoholic Hepatitis
MELD Accurately Predicts Mortality in Patients With Alcoholic Hepatitis Winston Dunn, 1 Laith H. Jamil, 1 Larry S. Brown, 2 Russell H. Wiesner, 1 W. Ray Kim, 1 K. V. Narayanan Menon, 1 Michael Malinchoc,
More informationPaul Martin, MD, FACG. University of Miami. 30,000 deaths from cirrhosis per annum, alcohol implicated in 48%
Paul Martin, MD, FACG University of Miami 30,000 deaths from cirrhosis per annum, alcohol implicated in 48% Second commonest indication for liver transplant NIAA 2007 Page 1 of 26 Risk Factors Medical
More informationA lcoholic hepatitis is perhaps the most florid manifestation
1174 ALCOHOLIC LIVER DISEASE Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score E H Forrest, C D J Evans, S Stewart,
More informationAmmonia level at admission predicts in-hospital mortality for patients with alcoholic hepatitis
Gastroenterology Report, 5(3), 2017, 232 236 doi: 10.1093/gastro/gow010 Advance Access Publication Date: 1 May 2016 Original article ORIGINAL ARTICLE Ammonia level at admission predicts in-hospital mortality
More informationTherapeutic Strategy in Severe Alcoholic Hepatitis: Present to future development of New
Therapeutic Strategy in Severe Alcoholic Hepatitis: Present to future development of New Philippe Mathurin Service Maladies de l Appareil Digestif Inserm U995 Hôpital Claude Huriez Lille France molecules
More informationWhite cell count and platelet count associate with histological alcoholic hepatitis in jaundiced harmful drinkers
Hardy et al. BMC Gastroenterology 2013, 13:55 RESEARCH ARTICLE Open Access White cell count and platelet count associate with histological alcoholic hepatitis in jaundiced harmful drinkers Timothy Hardy
More informationManagement of alcoholic hepatitis: Implications for options beyond the STOPAH study
Management of alcoholic hepatitis: Implications for options beyond the STOPAH study Gyongyi Szabo, MD, PhD Professor University of Massachusetts Medical School Worcester, MA Cape Town, South Africa 2015
More informationAlcoholic Hepatitis: Routine Screening for Early Recognition and Management. Juan Guerrero, MD
Alcoholic Hepatitis: Routine Screening for Early Recognition and Management Juan Guerrero, MD Global Problem 1% of GNP of medium/high income countries Additional societal costs Disproportionately affects
More informationAlcoholic Hepatitis: Management Options
Alcoholic Hepatitis: Management Options Paul J. Thuluvath, MD. FRCP Institute of Digestive Health & Liver Diseases, Mercy Medical Center, Baltimore Professor of Surgery & Medicine, Georgetown University,
More informationConflicts of Interest in the last 12 months
STEATOHEPATITIS Richard K. Sterling, MD, MSc, FACP, FACG VCU Hepatology Professor of Medicine Chief, Section of Hepatology Virginia Commonwealth University Richmond, VA Conflicts of Interest in the last
More informationAlcoholic hepatitis (AH), in its severe form, is associated
LIVER FAILURE AND LIVER DISEASE Early Change in Bilirubin Levels Is an Important Prognostic Factor in Severe Alcoholic Hepatitis Treated With Prednisolone Philippe Mathurin, 1,2 Marcelle Abdelnour, 3,5
More informationPrednisolone or Pentoxifylline for Alcoholic Hepatitis
The new england journal of medicine Original Article Prednisolone or Pentoxifylline for Alcoholic Hepatitis Mark R. Thursz, M.D., Paul Richardson, M.D., Michael Allison, Ph.D., Andrew Austin, M.D., Megan
More informationACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries
ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries Ashwani K. Singal, MD, MS, FACG 1, Ramon Bataller, MD, PhD, FACG 2, Joseph Ahn, MD, MS, FACG (GRADE Methodologist) 3, Patrick S. Kamath,
More informationTranscription factors in airway diseases
& 2006 USCAP, Inc All rights reserved 0023-6837/06 $30.00 www.laboratoryinvestigation.org Peter J Barnes Section of airway diseases, National Heart & Lung Institute, Imperial College, London, UK Transcription
More informationALCOHOLIC LIVER DISEASE (ALD) Nayan Patel, DO Transplant Hepatology/GI Banner Advanced Liver Disease and Transplant Center
ALCOHOLIC LIVER DISEASE (ALD) Nayan Patel, DO Transplant Hepatology/GI Banner Advanced Liver Disease and Transplant Center Objectives Spectrum of alcoholic liver disease Focus on Alcoholic Hepatitis (AH)
More informationManagement of autoimmune hepatitis. Pierre-Emmanuel RAUTOU Inserm U970, Paris Service d hépatologie, Hôpital Beaujon, Clichy, France
Management of autoimmune hepatitis Pierre-Emmanuel RAUTOU Inserm U970, PARCC@HEGP, Paris Service d hépatologie, Hôpital Beaujon, Clichy, France 41 year-old woman, coming to emergency department for fatigue
More informationManagement of Acute Decompensation of Cirrhosis JOHN O GRADY KING S COLLEGE HOSPITAL
Management of Acute Decompensation of Cirrhosis JOHN O GRADY KING S COLLEGE HOSPITAL Terminology Acute decompensation of cirrhosis - stable patient with sudden deterioration Acute-on-chronic liver failure
More informationSteroids or pentoxifylline for alcoholic hepatitis (STOPAH): study protocol for a randomised controlled trial
Forrest et al. Trials 2013, 14:262 TRIALS STUDY PROTOCOL Open Access Steroids or pentoxifylline for alcoholic hepatitis (STOPAH): study protocol for a randomised controlled trial Ewan Forrest 1, Jane Mellor
More informationMishra et al., IJPSR, 2018; Vol. 9(5): E-ISSN: ; P-ISSN:
IJPSR (2018), Volume 9, Issue 5 (Research Article) Received on 11 August, 2017; received in revised form, 01 February, 2018; accepted, 11 March, 2018; published 01 May, 2018 PROGNOSTIC UTILITY OF LILLE
More informationI have no disclosures relevant to this presentation LIVER TESTS: WHAT IS INCLUDED? LIVER TESTS: HOW TO UTILIZE THEM OBJECTIVES
LIVER TESTS: HOW TO UTILIZE THEM I have no disclosures relevant to this presentation José Franco, MD Professor of Medicine, Surgery and Pediatrics Medical College of Wisconsin OBJECTIVES Differentiate
More informationIncreased level of urinary nitric oxide metabolites in leprosy patients during Type 2 reactions and decreased after antireactional therapy
Lepr Rev (2007) 78, 386 390 Increased level of urinary nitric oxide metabolites in leprosy patients during Type 2 reactions and decreased after antireactional therapy KESHAR K. MOHANTY, MANISHA GUPTA,
More informationDRAFT FOR CONSULTATION
In patients with acute alcoholic hepatitis, what is the safety and efficacy of corticosteroids v placebo? Reference Carithers RL, Jr., Herlong HF, Diehl AM et al. Methylprednisolone therapy in patients
More informationPresentation and mortality of primary biliary cirrhosis in older patients
Age and Ageing 2000; 29: 305 309 Presentation and mortality of primary biliary cirrhosis in older patients JULIA L. NEWTON 1,DAVID E. JONES 2,JANE V. METCALF 2,JAY B. PARK 2,ALISTAIR D. BURT 2, MARGARET
More informationFOR OVER 40 yr, glucocorticoids have been used to treat a
0021-972X/99/$03.00/0 Vol. 84, No. 11 The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright 1999 by The Endocrine Society Wide Variation in Lymphocyte Steroid Sensitivity Among
More informationPatterns of abnormal LFTs and their differential diagnosis
Patterns of abnormal LFTs and their differential diagnosis Professor Matthew Cramp South West Liver Unit and Peninsula Schools of Medicine and Dentistry, Plymouth Outline liver function tests / tests of
More informationCase Report: Acute-on-Chronic Liver Failure: Making the Diagnosis between Infection and Acute Alcoholic Hepatitis
Diagnostic Problems in Hepatology 181 Case Report: Acute-on-Chronic Liver Failure: Making the Diagnosis between Infection and Acute Alcoholic Hepatitis Carmen Sendra, MD 1 Javier Ampuero, MD, PhD 1,2 Álvaro
More informationAnaesthetic considerations and peri-operative risks in patients with liver disease
Anaesthetic considerations and peri-operative risks in patients with liver disease Dr. C. K. Pandey Professor & Head Department of Anaesthesiology & Critical Care Medicine Institute of Liver and Biliary
More informationManagement of Alcoholic Liver Disease. Hafez Fakheri Professor of medicine, Sari, Iran
Management of Alcoholic Liver Disease Hafez Fakheri Professor of medicine, Sari, Iran Alcoholic Hepatitis Scores DF = (4.6 x [ PT- control PT]) + (bili ) MELD = 10 * ((0.957 * ln(cr)) + (0.378 * ln(bil))
More informationAlcoholism and Alcohol Liver Disease from a Transplant Hepatology Perspective
Alcoholism and Alcohol Liver Disease from a Transplant Hepatology Perspective Clark Kulig, MD Director, Porter Center for Liver Care Denver, CO February 2015 Does quantity of alcohol correlate with liver
More informationPatterns of abnormal LFTs and their differential diagnosis
Patterns of abnormal LFTs and their differential diagnosis Professor Matthew Cramp South West Liver Unit and Peninsula Schools of Medicine and Dentistry, Plymouth Outline liver function / liver function
More informationPBC features and management in the era of UDCA and Budesonide
PBC features and management in the era of UDCA and Budesonide Raoul Poupon, MD Université P&M Curie, AP-Hôpitaux de Paris, Inserm, Paris, France The changing pattern of PBC Over the last 2 decades: More
More informationType of intervention Treatment. Economic study type Cost-effectiveness analysis.
Albumin dialysis in cirrhosis with superimposed acute liver injury: possible impact of albumin dialysis on hospitalization costs Hassanein T, Oliver D, Stange J, Steiner C Record Status This is a critical
More informationCOPD and Asthma: Similarities and differences Prof. Peter Barnes
and Asthma: Similarities and Differences and Asthma: 1 Imperial College Peter Barnes FRS, FMedSci, National Heart & Lung Institute Imperial College, London, UK p.j.barnes@imperial.ac.uk Royal Brompton
More informationCHAPTER 1. Alcoholic Liver Disease
CHAPTER 1 Alcoholic Liver Disease Major Lesions of Alcoholic Liver Disease Alcoholic fatty liver - >90% of binge and chronic drinkers Alcoholic hepatitis precursor of cirrhosis Alcoholic cirrhosis end
More informationPredicting utility of a model for end stage liver disease in alcoholic liver disease
PO Box 2345, Beijing 00023, China World J Gastroenterol 2006 July 7; 2(25): 4020-4025 World Journal of Gastroenterology ISSN 007-9327 wjg@wjgnet.com 2006 The WJG Press. All rights reserved. CLINICAL RESEARCH
More informationSteroids in ARDS: if, when, how much? John Fowler, MD, FACEP Dept. of Emergency Medicine Kent Hospital, İzmir, Türkiye
Steroids in ARDS: if, when, how much? John Fowler, MD, FACEP Dept. of Emergency Medicine Kent Hospital, İzmir, Türkiye Steroids in ARDS: conclusion Give low-dose steroids if indicated for another problem
More informationKey words: systemic lupus erythematosus (SLE), monocyte, priming effect, polymorphnuclear neutrophils-chemiluminescence corticosteroid
Key words: systemic lupus erythematosus (SLE), monocyte, priming effect, polymorphnuclear neutrophils-chemiluminescence corticosteroid (PMN-CL), Table 1 Patient profiles PSL: prednisolone,*: duration of
More informationCurrent Asthma Management: Opportunities for a Nutrition-Based Intervention
Current Asthma Management: Opportunities for a Nutrition-Based Intervention Stanley J. Szefler, MD Approximately 22 million Americans, including 6 million children, have asthma. It is one of the most prevalent
More informationSuspected Isoflurane Induced Hepatitis from Cross Sensitivity in a Post Transplant for Fulminant Hepatitis from Halothane.
ISPUB.COM The Internet Journal of Anesthesiology Volume 25 Number 1 Suspected Isoflurane Induced Hepatitis from Cross Sensitivity in a Post Transplant for Fulminant Hepatitis from Halothane. V Sampathi,
More informationBack to the Future: Updated Guidelines for Evaluation and Management of Adrenal Insufficiency in the Critically Ill
Back to the Future: Updated Guidelines for Evaluation and Management of Adrenal Insufficiency in the Critically Ill Joe Palumbo PGY-2 Critical Care Pharmacy Resident Buffalo General Medical Center Disclosures
More informationPUBLICATIONS. cells. J. Physiol. (London) 517P:91P (Manchester, England, UK).
277 PUBLICATIONS Abstracts Haddad JJ, Land SC (1999). Differential activation of oxygen-responsive transcription factors over fetal-to-neonatal alveolar oxygen tensions in rat fetal distal lung epithelial
More informationPrognostic models for alcoholic hepatitis
Rahimi and Pan Biomarker Research (2015) 3:20 DOI 10.1186/s40364-015-0046-z REVIEW Prognostic models for alcoholic hepatitis Erik Rahimi * and Jen-Jung Pan Open Access Abstract Alcoholic hepatitis (AH)
More informationHepatology For The Nonhepatologist
Hepatology For The Nonhepatologist Andrew Aronsohn, MD Associate Professor of Medicine University of Chicago Chicago, Illinois Learning Objectives After attending this presentation, learners will be able
More informationTHE PHARMA INNOVATION - JOURNAL Immune Corrective Role of Statin Therapy in Patients with Chronic Obstructive Pulmonary Disease and Metabolic Syndrome
Received: 19-07-2013 Accepted: 18-08-2013 ISSN: 2277-7695 CODEN Code: PIHNBQ ZDB-Number: 2663038-2 IC Journal No: 7725 Vol. 2 No. 8 2013 Online Available at www.thepharmajournal.com THE PHARMA INNOVATION
More informationASH 2011 aktualijos: MSC TPŠL gydyme. Mindaugas Stoškus VULSK HOTC MRMS
ASH 2011 aktualijos: MSC TPŠL gydyme Mindaugas Stoškus VULSK HOTC MRMS #3042. Yukiyasu Ozawa et al. Mesenchymal Stem Cells As a Treatment for Steroid-Resistant Acute Graft Versus Host Disease (agvhd);
More informationTHE PHARMA INNOVATION - JOURNAL Clinical Characteristics of Chronic Obstructive Pulmonary Disease
Received: 09012014 Accepted: 30032014 ISSN: 2277 7695 CODEN Code: PIHNBQ ZDBNumber: 26630382 IC Journal No: 7725 Vol. 3 No. 2. 2014 Online Available at www.thepharmajournal.com THE PHARMA INNOVATION JOURNAL
More informationPrognosis of untreated Primary Sclerosing Cholangitis (PSC) Erik Christensen Copenhagen, Denmark
Prognosis of untreated Primary Sclerosing Cholangitis (PSC) Erik Christensen Copenhagen, Denmark Study of Prognosis of PSC Difficulties: Disease is rare The duration of the course of disease may be very
More informationImmunosuppressants. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Immunosuppressants Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Immunosuppressive Agents Very useful in minimizing the occurrence of exaggerated or inappropriate
More informationKing s College Hospital NHS Foundation Trust. Acute on Chronic Liver Failure: Practical management outside the tertiary centre.
King s College Hospital NHS Foundation Trust NHS Acute on Chronic Liver Failure: Practical management outside the tertiary centre. William Bernal Professor of Liver Critical Care Liver Intensive Therapy
More informationHBV Therapy in Special Populations: Liver Cirrhosis
HBV Therapy in Special Populations: Liver Cirrhosis Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber- und Studienzentrum
More informationAND COPD ADVANCES IN COMBINATION THERAPY FOR ASTHMA. Jan Lotvall. Editor. Krefting Research Centre, University of Gothenburg,
ADVANCES IN COMBINATION THERAPY FOR ASTHMA AND COPD Editor Jan Lotvall Krefting Research Centre, University of Gothenburg, Sweden A Wiley Sons, Ltd., Publication Contents Contributors xi Preface 1 Similarities
More informationIntegrated Cardiopulmonary Pharmacology Third Edition
Integrated Cardiopulmonary Pharmacology Third Edition Chapter 13 Pharmacologic Management of Asthma, Chronic Bronchitis, and Emphysema Multimedia Directory Slide 7 Slide 12 Slide 60 COPD Video Passive
More informationSearching for Targets to Control Asthma
Searching for Targets to Control Asthma Timothy Craig Distinguished Educator Professor Medicine and Pediatrics Penn State University Hershey, PA, USA Inflammation and Remodeling in Asthma The most important
More informationInfection does not increase long-term mortality in patients with acute severe alcoholic hepatitis treated with corticosteroids
Submit a Manuscript: http://www.wjgnet.com/esps/ DOI: 10.3748/wjg.v23.i11.2052 World J Gastroenterol 2017 March 21; 23(11): 2052-2059 ISSN 1007-9327 (print) ISSN 2219-2840 (online) ORIGINAL ARTICLE Observational
More informationDiagnosis and Monitoring of Avian Hepatic Disease. Sue Jaensch 1. Clinical Signs
Diagnosis and Monitoring of Avian Hepatic Disease Sue Jaensch 1 linical Signs The clinical presentation of birds with liver disease is typically non-specific and variable. Presenting signs may include
More informationClinical efficacy of montelukast in anti-inflammatory treatment of asthma and allergic rhinitis
Clinical efficacy of montelukast in anti-inflammatory treatment of asthma and allergic rhinitis Kim Hyun Hee, MD, PhD. Dept. of Pediatrics The Catholic University of Korea College of Medicine Achieving
More informationBUDESONIDE AND FORMOTEROL (SYMBICORT ): Α A REVIEW
Volume 23, Issue 3 December 2007 BUDESONIDE AND FORMOTEROL (SYMBICORT ): A REVIEW Donna L. Smith, Pharm. D. Candidate More than 22 million people in the United States have asthma according to the Centers
More informationPharmacology of Corticosteroids
Pharmacology of Corticosteroids Dr. Aliah Alshanwani Dept. of Pharmacology College of Medicine, KSU Feb 2018 1 The Corticosteroids are steroid hormones produced by the adrenal cortex. They consist of two
More informationEuropean. Young Hepatologists Workshop. Organized by : Quantification of fibrosis and cirrhosis outcomes
supported by from Gilea Quantification of fibrosis and cirrhosis outcomes th 5 European 5 European Young Hepatologists Workshop Young Hepatologists Workshop August, 27-29. 2015, Moulin de Vernègues Vincenza
More informationSarcoidosis Case. Robert P. Baughman Interstitial Lung Disease and Sarcoidosis Clinic University of Cincinnati, USA. WASOG: educational material
Sarcoidosis Case Robert P. Baughman Interstitial Lung Disease and Sarcoidosis Clinic University of Cincinnati, USA WASOG: educational material Sarcoidosis Case patient is a Caucasian male age 46 was diagnosed
More informationAdrenal Insufficiency in Patients with Liver Cirrhosis and Severe Sepsis: Effect on Survival after Treatment with Hydrocortisone ABSTRACT
20 Original Article Adrenal Insufficiency in Patients with Liver Cirrhosis and Severe Sepsis: Effect on Survival after Treatment with Hydrocortisone Pattanasirigool C Prasongsuksan C Settasin S Letrochawalit
More informationAt least 3 of the following criteria:
Management of Severe Asthma Heung-Woo Park Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea How to define severe asthma At least 3 of the following criteria:
More informationKey Aspects of Diagnosing Alcoholic Hepatitis. Mark Sonderup University of Cape Town & Groote Schuur Hospital
Key Aspects of Diagnosing Alcoholic Hepatitis Mark Sonderup University of Cape Town & Groote Schuur Hospital 42 year old woman, married with 3 children No significant co-morbidities or illnesses Habits
More informationBariatric Surgery For Patients With End-Organ Failure
Bariatric Surgery For Patients With End-Organ Failure Arnold D. Salzberg, M.D. Andrew M. Posselt, M.D., PhD Divisions of Transplant and Minimally Invasive Surgery University of California, San Francisco
More informationAlpha-1 Antitrypsin Deficiency and Augmentation Therapy-Prolastin-C Post Test
Alpha-1 Antitrypsin Deficiency and Augmentation Therapy-Prolastin-C Post Test 1. Persons with Alpha-1 are at high risk for developing life-threatening liver disease for which of the following reasons?
More informationUtilizing AlphaLISA Technology to Screen for Inhibitors of the CTLA-4 Immune Checkpoint
APPLICATION NOTE AlphaLISA Technology Authors: Matthew Marunde Stephen Hurt PerkinElmer, Inc. Hopkinton, MA Utilizing AlphaLISA Technology to Screen for Inhibitors of the CTLA-4 Immune Checkpoint Introduction
More informationAssay Report. Histone Deacetylase (HDAC) Inhibitor Assays Enzymatic Study of Compounds from Client
Assay Report Histone Deacetylase (HDAC) Inhibitor Assays Enzymatic Study of Compounds from Client Page 1 of 27 Client_HDAC _Year Month Day 1 Client_HDAC_Year Month Year HDAC Inhibitor Assays Study Sponsor:
More informationAutoimmune Hepatitis: Defining the need for Liver Transplantation
Autoimmune Hepatitis: Defining the need for Liver Transplantation Michael A Heneghan, MD, MMedSc, FRCPI. Institute of Liver Studies, King s College Hospital, London Outline Autoimmune Hepatitis Background
More informationA Day-4 Lille Model Predicts Response to Corticosteroids and Mortality in Severe Alcoholic Hepatitis
306 ORIGINAL CONTRIBUTIONS see related editorial on page x A Day-4 Lille Model Predicts Response to Corticosteroids and Mortality in Severe Alcoholic Hepatitis Mauricio Garcia-Saenz-de-Sicilia, MD 1, 9,
More informationNorepinephrine versus Terlipressin for the Treatment of Hepatorenal Syndrome
Norepinephrine versus Terlipressin for the Treatment of Hepatorenal Syndrome Disclosure I have no conflicts of interest to disclose Name: Margarita Taburyanskaya Title: PharmD, PGY1 Pharmacy Practice Resident
More informationImpact of Asthma in the U.S. per Year. Asthma Epidemiology and Pathophysiology. Risk Factors for Asthma. Childhood Asthma Costs of Asthma
American Association for Respiratory Care Asthma Educator Certification Prep Course Asthma Epidemiology and Pathophysiology Robert C. Cohn, MD, FAARC MetroHealth Medical Center Cleveland, OH Impact of
More informationEarly life determinants of Non-Alcoholic Fatty Liver Disease and NASH DR JULIANA MUIVA-GITOBU KENYA PAEDIATRIC ASSOCIATION CONFERENCE APRIL 2016.
Early life determinants of Non-Alcoholic Fatty Liver Disease and NASH DR JULIANA MUIVA-GITOBU KENYA PAEDIATRIC ASSOCIATION CONFERENCE APRIL 2016. Outline Definition NAFLD and NASH Magnitude of the problem
More informationChapter 7 Conclusions
VII-1 Chapter 7 Conclusions VII-2 The development of cell-based therapies ranging from well-established practices such as bone marrow transplant to next-generation strategies such as adoptive T-cell therapy
More informationHepatocytes produce. Proteins Clotting factors Hormones. Bile Flow
R.J.Bailey MD Hepatocytes produce Proteins Clotting factors Hormones Bile Flow Trouble.. for the liver! Trouble for the Liver Liver Gall Bladder Common Alcohol Hep C Fatty Liver Cancer Drugs Viruses Uncommon
More informationManagement of Decompensated Chronic Hepatitis B
Management of Decompensated Chronic Hepatitis B Dr James YY Fung, FRACP, MD Department of Medicine The University of Hong Kong Liver Transplant Center Queen Mary Hospital State Key Laboratory for Liver
More informationIntron A Hepatitis C. Intron A (interferon alfa-2b) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.05 Subject: Intron A Hepatitis C Page: 1 of 5 Last Review Date: November 30, 2018 Intron A Hepatitis
More informationDecramer 2014 a &b [21]
Buhl 2015 [19] Celli 2014 [20] Decramer 2014 a &b [21] D Urzo 2014 [22] Maleki-Yazdi 2014 [23] Inclusion criteria: Diagnosis of chronic obstructive pulmonary disease; 40 years of age or older; Relatively
More informationDiscussing Prognosis. David Ross Russell MD ProHealth Physicians Inc.
Discussing Prognosis David Ross Russell MD ProHealth Physicians Inc. Prognosis- peeling back the layers Not a new Science Psalm 39 LORD, make me to know mine end, and the measure of my days. Hippocrates
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: The National Heart, Lung, and Blood Institute Acute Respiratory
More informationJOURNAL PRESENTATION. Dr Tina Fan Tseung Kwan O Hospital 17 th Jan 2013
JOURNAL PRESENTATION Dr Tina Fan Tseung Kwan O Hospital 17 th Jan 2013 THE COMBINATION OF OCTREOTIDE AND MIDODRINE IS NOT SUPERIOR TO ALBUMIN IN PREVENTING RECURRENCE OF ASCITES AFTER LARGE-VOLUME PARACENTESIS
More informationPrise en charge de l hépatite alcoolique aiguë
Prise en charge de l hépatite alcoolique aiguë Prof Christophe Moreno M.D. Ph.D. Clinical Director, Liver Unit Dept. of Gastroenterology, Hepato-Pancreatology and Digestive Oncology CUB Hôpital Erasme
More informationAlcoholic Liver Disease Strategies for Seamless Care or An Clinical Approach to the Jaundiced Alcoholic Patient
Alcoholic Liver Disease Strategies for Seamless Care or An Clinical Approach to the Jaundiced Alcoholic Patient Liver Disease for the General Physician Royal College of Physicians July 2017 Dr Ewan Forrest
More informationImmunological Aspect of Ozone in Rheumatic Diseases
Immunological Aspect of Ozone in Rheumatic Diseases Prof. Dr. med. Z. Fahmy Chief Consulting Rheumatologist Augusta Clinic for Rheumatic Diseases And Rehabilitation Bad Kreuznach Germany Rheumatoid arthritis
More informationtenofovir disoproxil (as fumarate), 245mg, film-coated tablet (Viread ) SMC No. (720/11) Gilead Sciences Ltd
tenofovir disoproxil (as fumarate), 245mg, film-coated tablet (Viread ) SMC No. (720/11) Gilead Sciences Ltd 05 August 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of the above
More informationAutoimmune Hepatitis in Clinical Practice
1 Autoimmune Hepatitis in Clinical Practice Atif Zaman, MD MPH Professor of Medicine Senior Associate Dean for Clinical and Faculty Affairs School of Medicine Oregon Health & Science University Disclosure
More informationCorticosteroids. Hawler Medical University College of Medicine Department of Pharmacology and Biophysics Dr.Susan Abdulkadir Farhadi MSc Pharmacology
Corticosteroids Hawler Medical University College of Medicine Department of Pharmacology and Biophysics Dr.Susan Abdulkadir Farhadi MSc Pharmacology Objectives By the end of this lecture you should be
More informationThe number of patients with alcoholic liver disease
December 2000 EDITORIALS 1787 Pentoxifylline and Alcoholic Hepatitis See article on page 1637. The number of patients with alcoholic liver disease (ALD) in the United States is unknown and probably underestimated
More informationThe management of alcoholic liver disease
Journal of Hepatology 38 (2003) S2 S13 www.elsevier.com/locate/jhep The management of alcoholic liver disease Stephen F. Stewart, Christopher P. Day* Centre for Liver Research, Medical School, Framlington
More informationSydney, AUSTRALIA Beijing, CHINA Hyderabad, INDIA Oxford, UK. Affiliated with
Sydney, AUSTRALIA Beijing, CHINA Hyderabad, INDIA Oxford, UK Affiliated with COPD and Comorbidities Norbert Berend Professor Emeritus University of Sydney Head, Respiratory Research The George Institute
More informationPrescribed Minimum Benefits treatment guidelines 2013
Prescribed Minimum Benefits treatment guidelines 20 Treatment guidelines for the Prescribed Minimum Benefit chronic conditions 20 The Chronic Illness Benefit covers a limited number of tests and each for
More informationRoflumilast (Daxas) for chronic obstructive pulmonary disease
Roflumilast (Daxas) for chronic obstructive pulmonary disease August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationThree triggers that suggest that patients could benefit from a hospice palliative care approach
Why is it important to identify people nearing the end of life? About 1% of the population dies each year. Although some deaths are unexpected, many more in fact can be predicted. This is inherently difficult,
More informationControversies in Management of Portal Hypertension and Cirrhosis Complications in the Transplant Candidate
Controversies in Management of Portal Hypertension and Cirrhosis Complications in the Transplant Candidate Patrick Northup, MD, FAASLD, FACG Medical Director, Liver Transplantation University of Virginia
More informationCASE 1 Plasma Cell Infiltrates: Significance in post liver transplantation and in chronic liver disease
CASE 1 Plasma Cell Infiltrates: Significance in post liver transplantation and in chronic liver disease Maria Isabel Fiel, M.D. The Mount Sinai Medical Center New York, New York Case A 57 yo man, 7 months
More informationThe Chronic Liver Disease Foundation (CLDF) and the International Coalition of Hepatology Education Providers (IC-HEP) present:
The Chronic Liver Disease Foundation (CLDF) and the International Coalition of Hepatology Education Providers (IC-HEP) present: Certified by: Provided by: Endorsed by: Hepatic Encephalopathy Hepatic Encephalopathy:
More information